Nearly every published study related to the treatment of patients with pancreatic ductal adenocarcinoma (PDAC) opens with a description of the poor long-term survival associated with the diagnosis, and many further emphasize that resection is the only potentially curative treatment option. While both points are for the most part factual, neither really tells the whole story. With contemporary systemic therapy regimens, long-term survivors are increasingly identified.1 There is also an evolving understanding that while surgery is potentially curative, this is particularly the case when it is not used as a stand-alone intervention but rather incorporated as part of multimodality therapy (MMT) that includes chemotherapy, concurrent chemoradiotherapy, or both.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
da Costa WL, Tran Cao HS, Massarweh NN. Neoadjuvant Treatment for Patients With Localized Pancreatic Adenocarcinoma: Are We There Yet? JAMA Oncol. Published online May 28, 2020. doi:10.1001/jamaoncol.2020.0562
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: